Genetic testing for heterozygous familial hypercholesterolemia (FH)
Customize your policy alerts
Sign up for Capital Bluecross Policy MP 2.363 alerts
Get alerted when Policy MP 2.363 changes without checking for updates manually.
Monitor payer policy activity
This policy governs when genetic testing to confirm heterozygous familial hypercholesterolemia is considered medically necessary or investigational for members covered by Capital Bluecross; it addresses index cases, testing of children of affected parents, and testing of adult relatives. Applies to programs and products administered by Capital Bluecross as noted.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.